225 related articles for article (PubMed ID: 16673599)
1. Urinary prostate specific antigen: is the clinical use likely?
Pejcic T; Hadzi-Djokic J; Acimovic M; Topuzovic C; Milkovic B; Janjic A
Acta Chir Iugosl; 2005; 52(4):69-74. PubMed ID: 16673599
[TBL] [Abstract][Full Text] [Related]
2. Urinary PSA in monitoring of patients with prostate cancer.
Pejcić T; Dimitrijević V; Hadzi-Djokić J
Acta Chir Iugosl; 2012; 59(1):57-60. PubMed ID: 22924305
[TBL] [Abstract][Full Text] [Related]
3. Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression?
Pejcic TP; Tulic CDz; Lalic NV; Glisic BD; Ignjatovic SD; Markovic BB; Hadzi-Djokic JB
Can J Urol; 2013 Apr; 20(2):6707-13. PubMed ID: 23587511
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of patients with diseases of the prostate using prostate-specific antigen density.
Wolff JM; Boeckmann W; Effert PJ; Handt S; Jakse G
Br J Urol; 1995 Jul; 76(1):41-6. PubMed ID: 7544203
[TBL] [Abstract][Full Text] [Related]
5. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
6. Urinary PSA level and relative tumor volume after prostate biopsy.
Pejcić T; Hadzi-Djokić J; Marković B; Dragićević D; Glisić B; Lalić N; Aćimović M; Dzamić Z; Radosavljevic R
Acta Chir Iugosl; 2009; 56(2):17-21. PubMed ID: 19780325
[TBL] [Abstract][Full Text] [Related]
7. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
[TBL] [Abstract][Full Text] [Related]
8. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
[TBL] [Abstract][Full Text] [Related]
9. An algorithm for prostate cancer detection in a patient population using prostate-specific antigen and prostate-specific antigen density.
Benson MC; McMahon DJ; Cooner WH; Olsson CA
World J Urol; 1993; 11(4):206-13. PubMed ID: 7508785
[TBL] [Abstract][Full Text] [Related]
10. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen: insufficient discrimination between benign prostatic hyperplasia and organ-confined prostate cancer.
Wolff JM; Boeckmann W; Borchers H; Handt S; Reineke T; Jakse G
Urol Int; 1996; 57(3):170-4. PubMed ID: 8912446
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen in urine.
Breul J; Pickl U; Hartung R
Eur Urol; 1994; 26(1):18-21. PubMed ID: 7523129
[TBL] [Abstract][Full Text] [Related]
13. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
[TBL] [Abstract][Full Text] [Related]
14. Ultrasensitive prostate specific antigen assay following laparoscopic radical prostatectomy--an outcome measure for defining the learning curve.
Viney R; Gommersall L; Zeif J; Hayne D; Shah ZH; Doherty A
Ann R Coll Surg Engl; 2009 Jul; 91(5):399-403. PubMed ID: 19409146
[TBL] [Abstract][Full Text] [Related]
15. Prostate biopsy in patients with long-term use of indwelling bladder catheter: what is the rationale?
Antunes AA; Barbosa JA; Reis ST; Guariero MS; Fukushima JT; Dall'oglio MF; Freire Gde C; Lucon AM; Leite KR; Srougi M
Urol Oncol; 2012 Sep; 30(5):620-3. PubMed ID: 20933446
[TBL] [Abstract][Full Text] [Related]
16. Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage.
Scattoni V; Roscigno M; Raber M; Montorsi F; Da Pozzo L; Guazzoni G; Freschi M; Rigatti P
Eur Urol; 2003 Oct; 44(4):407-14. PubMed ID: 14499673
[TBL] [Abstract][Full Text] [Related]
17. An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands.
Iwakiri J; Granbois K; Wehner N; Graves HC; Stamey T
J Urol; 1993 Apr; 149(4):783-6. PubMed ID: 7681118
[TBL] [Abstract][Full Text] [Related]
18. Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia.
Marley GM; Miller MC; Kattan MW; Zhao G; Patton KP; Vessella RL; Wright GL; Schellhammer PF; Veltri RW
Urology; 1996 Dec; 48(6A Suppl):16-22. PubMed ID: 8973695
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD
S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554
[TBL] [Abstract][Full Text] [Related]
20. Cytokeratin 8/18 levels in patients with prostate cancer and benign prostatic hyperplasia.
Wolff JM; Borchers H; Brehmer B; Brauers A; Jakse G
Urol Int; 1998; 60(3):152-5. PubMed ID: 9644784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
